The Angiotensin-Converting Enzyme Inhibitor ‘Enalapril’ Increases the Anti-Proliferative Activity of 5-Fluorouracil in Colorectal Cancer Cells
Objectives: The dysregulation of angiotensin-converting enzyme inhibitor (ACE-I) and its pathway has been reported to be associated with oncogenesis and poor prognosis in colorectal cancer (CRC).
Methods: We explored the therapeutic potential of targeting ACE-I through the use of enalapril and investigated its pharmacological interaction with 5-FU in CT26, HT29, and SW480 cells. The anti-proliferative and anti-migratory effects as well as apoptotic activity of this agent on cell cycle have been evaluated by MTT, wound healing assay, and FACS, while the expression of genes was determined through mRNA or protein levels.
Results: According to the observations, enalapril has inhibited cell proliferation in a dose-dependent manner and affected the anti-tumor properties of 5-FU via increasing the levels of apoptosis and ROS, as well as through the modulation of antioxidant/oxidant markers. Enalapril has also suppressed cell migration by the perturbation of MMP3/MMP-9 and E-cadherin. The combination of enalapril and 5FU has resulted in decrease in the expression levels of ACE, AT1R, and SMAD-3.
Conclusion: Our findings suggested that targeting ACE-I by applying the modulation of angiotensin pathway could increase the activity of 5-FU due to interfering with cell-proliferation, apoptosis, and inflammatory markers, which is indicative of its potential value as a therapeutic option for the treatment of CRC.
1.Hashemzehi M, Naghibzadeh N, Asgharzadeh F, Mostafapour A, Hassanian SM, Ferns GA, et al. The therapeutic potential of losartan in lung metastasis of colorectal cancer. EXCLI J 2020;19:927–35.
2. Stoeltzing O, Liu W, Reinmuth N, Parikh A, Ahmad SA, Jung YD, et al. New approaches to the treatment of hepatic malignancies angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Ann S Oncol 2003;10:722–33.
3. Moses HL, Yang EY, Pietenpol JA. TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights. Cell 1990;63:245–7.
4. Massagué J. G1 cell-cycle control and cancer. Nature 2004;432:298–306.
5. Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T. Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol 2004;43:142–52.
6. Kerbel RS. Clinical trials of antiangiogenic drugs: Opportunities, problems, and assessment of initial results. J Clin Oncol 2001;19:45–51.
7. Kim SI, Kwak JH, Na H-J, Kim JK, Ding Y, Choi ME. Transforming growth factor-β (TGF-β1) activates TAK1 via TAB1-mediated autophosphorylation, independent of TGF-β receptor kinase activity in mesangial cells. J Biol Chem 2009;284:22285–96.
8. Ludwig L, Kessler H, Wagner M, Hoang-Vu C, Dralle H, Adler G, et al. Nuclear factor-κB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res 2001;61:4526–35.
9. Strippoli GF, Bonifati C, Craig ME, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006;2006:006257.
10. Du N, Feng J, Hu L-J, Sun X, Sun H-B, Zhao Y, et al. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling. Oncol Rep 2012;27:1893–903.
11. Osumi H, Matsusaka S, Wakatsuki T, Suenaga M, Shinozaki E, Mizunuma N. Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. Mol Clin Oncol 2015;3:1295–300.
12. Puddefoot J, Udeozo U, Barker S, Vinson G. The role of angiotensin II in the regulation of breast cancer cell adhesion and invasion. Endocr Relat Cancer 2006;13:895–903.
13. Ribatti D, Conconi MT, Nussdorfer GG. Nonclassic endogenous novel regulators of angiogenesis. Pharmacol Rev 2007;59:185–205.
14. Zhao Y, Chen X, Cai L, Yang Y, Sui G, Wu J. Angiotensin II suppresses adriamycin‐induced apoptosis through activation of phosphatidylinositol 3‐kinase/Akt signaling in human breast cancer cells. Acta Biochim Biophys Sin 2008;40:304–10.
15. Papageorgis P, Cheng K, Ozturk S, Gong Y, Lambert AW, Abdolmaleky HM, et al. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res 2011;71:998– 1008.
16. Samuel S, Fan F, Dang LH, Xia L, Gaur P, Ellis LM. Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene 2011;30:1205–12.
17. Rivera E, Arrieta O, Guevara P, Duarte-Rojo A, Sotelo J. AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer 2001;85:1396–9.
18. El Bekay R, Alvarez M, Monteseirín J, Alba G, Chacón P, Vega A, et al. Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: Involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-κB. Blood 2003;102:662–71.
19. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor. Clin Cancer Res 2001;7:1073–8.
20. Williams R, Parsons S, Morris T, Rowlands B, Watson S. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol 2005;31:1042–50.
21. de Groot‐Besseling RR, Ruers TJ, van Kraats AA, Poelen GJ, Ruiter DJ, de Waal RM, et al. Anti‐tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. Int J Cancer 2004;112:329–34.
22. Wysocki PJ, Kwiatkowska EP, Kazimierczak U, Suchorska W, Kowalczyk DW, Mackiewicz A. Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice. Clin Cancer Res 2006;12:4095–102.
23. Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004;22:820–8.